Beyondspring (BYSI) Aktsia Kursus
Beyondspring Kursus
Käive kasvas 113,5 % aastas viimase 3 aasta jooksul 1,75 M USD-ni. Beyondspring netomarginaal on nüüd −1200,8 %, tõusnud −33 873,9 %-lt mõni aasta tagasi. Analüütikute hinnasihi mediaan on 1,28 USD, st üle praegust hinda 109,1 %. 7 analüütikust 6 soovitab osta — üldine konsensus on Osta.
Beyondspring aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Beyondspring ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Beyondspring aktsia kohta
The business model of Beyondspring Inc revolves around the development and commercialization of innovative immuno-oncology drugs. They focus on creating new treatment options for patients with high unmet medical needs, particularly in the areas of cancer and inflammatory diseases. Beyondspring Inc aims to leverage their expertise in immuno-oncology, research, and development, alongside strategic partnerships, to advance their drug candidates and bring them to market. Their commitment to improving patient outcomes and addressing critical medical challenges drives their business approach and guides their efforts in developing cutting-edge therapies for the benefit of individuals worldwide.
Beyondspring Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Beyondspring Inc in the market include companies such as Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, and Merck & Co., Inc.
Beyondspring Inc. is a biopharmaceutical company focused on the development of innovative cancer therapies. Founded in 2012 and headquartered in New York, the company is dedicated to improving the lives of patients by advancing its extensive pipeline of promising drug candidates. Beyondspring Inc. specializes in the development of innovative immuno-oncology drugs and novel targeted therapies. With a strong team of experienced professionals and strategic partnerships, the company is committed to bringing new treatment options to patients suffering from serious and life-threatening illnesses. Beyondspring Inc. continues to grow and make significant advancements in the field of cancer therapeutics.
Beyondspring Inc has achieved several significant milestones that have propelled the company's growth and success. Notably, the company successfully completed Phase 3 clinical trials for its lead product, Plinabulin, as a potential breakthrough in chemotherapy-induced neutropenia. Beyondspring Inc also obtained Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for Plinabulin, expanding its potential market reach and driving investor confidence. Moreover, the company forged key partnerships and collaborations with renowned institutions to further advance its innovative pipeline and enhance its market position. These achievements highlight Beyondspring Inc's commitment to delivering cutting-edge solutions and positioning itself as a leader in the biopharmaceutical industry.
Beyondspring Inc is primarily present in the United States and China.
Beyondspring Inc is a leading pharmaceutical company that is committed to transforming the lives of patients through innovative and cutting-edge medical solutions. The company's corporate philosophy revolves around scientific excellence, patient-centricity, and integrity. Beyondspring Inc firmly believes in developing groundbreaking therapies that address unmet medical needs and improve patient outcomes. By fostering a culture of innovation and collaboration, the company aims to revolutionize the field of oncology and provide hope to patients around the world. Beyondspring Inc's dedication to advancing medical breakthroughs reflects their commitment to delivering value and making a positive impact in the healthcare industry.
Analüütikud määravad Beyondspring aktsiale keskmiseks hinnasihi 1,28 USD (mediaan: 1,28 USD), mis on +109,1 % viimase hinna suhtes. Konsensus põhineb 7 analüütiku hinnangul.
7 analüütikut hindavad praegu Beyondspring aktsiat: 6 soovitab osta, 1 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et Beyondspring teenib tulu 194,65 M USD ja kasumit aktsia kohta 1,95 USD.
Praeguse kursiga kaubeldakse Beyondspring aktsiaga 0,54 EUR (0,61 USD) juures.
Beyondspring aktsia (BYSI) on noteeritud 1 börsil, sh: NASDAQ (BYSI).
Beyondspring Inc is a biopharmaceutical company focused on researching and developing innovative cancer therapies. The company is headquartered in New York, USA, and has research and development facilities in the USA and China. Its business model is centered around identifying and developing cancer therapies that have the potential to improve the lives of patients worldwide. It particularly focuses on developing drugs for the treatment of blood and lymphatic system cancers, as well as those that counteract the side effects associated with chemotherapy. Beyondspring Inc's research and development activities are divided into two main areas: innovative cancer therapies and supportive care products. The company has several innovative cancer therapies in various stages of development, with its most advanced drug being Plinabulin. This drug is being studied for the treatment of various cancers such as lung, stomach, and pancreatic cancer. Plinabulin is a novel cytoprotective antineoplastic agent that is able to kill cancer cells while protecting healthy cells. It is intended to be used in combination with other cancer therapies such as chemotherapy and immunotherapy. Beyondspring Inc also offers a range of supportive care products under the brand BeyondCare. These products help reduce the side effects of cancer therapies and improve the well-being of cancer patients. They include mouthwashes, moisturizers, and other care products specifically designed for cancer patients. The products are made with natural ingredients only, are hypoallergenic, and free from harmful chemicals. In conclusion, Beyondspring Inc's business model is focused on researching, developing, and marketing innovative cancer therapies and supportive care products. The company is dedicated to developing safe and effective cancer therapies with the aim of improving the lives of cancer patients worldwide. With its wide range of products and services, it positions itself as a key player in the healthcare industry and contributes to improving the quality of life for cancer patients.
oodatav Beyondspring käive on 194,65 M USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Beyondspring kasum on 78,67 M USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Beyondspring jaoks on praegu 0,31. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Beyondspring aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Beyondspring jaoks on praegu 0,13. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Beyondspring aktsia jaoks.
Eulpooli kvaliteedinäitaja Beyondspring jaoks on 2/10.
Beyondspring ISIN on KYG108301006. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Beyondspring WKN on A2DNMQ. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Beyondspring ticker on BYSI. Ticker-sümbol kasutatakse Beyondspring aktsiate kauplemiseks börsil.
Beyondspring aktsia
Beyondspring konkurendid
Beyondspring Börsiticker
Beyondspring FIGI
Kõik teised näitajad ja analüüsid Beyondspring kohta sügavamalt
Meie Beyondspring-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Beyondspring. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: